These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 523590)
21. Role of dopaminergic receptors in the regulation of growth hormone secretion. Müller EE; Liuzzi A; Cocchi D; Panerai AE; Oppizzi G; Lacatelli V; Mantegazza P; Silvestrini F; Chiodini PG Adv Biochem Psychopharmacol; 1977; 16():127-38. PubMed ID: 142419 [No Abstract] [Full Text] [Related]
22. [Significance of blood levels of prolactin and somatotropin as indices of pharmacological effects on the central nervous system]. Barreca T; Gallamini A; Murialdo G; Nizzo MC; Polleri A Clin Ter; 1978 Jul; 86(2):147-59. PubMed ID: 743856 [No Abstract] [Full Text] [Related]
23. Effect of dopamine and neuroleptics on plasma growth hormone and prolactin in normal men. Langer G; Sachar EJ; Halpern FS Psychoneuroendocrinology; 1978 Apr; 3(2):165-9. PubMed ID: 704750 [No Abstract] [Full Text] [Related]
24. Gonadal axis hormones in male schizophrenic patients during treatment with haloperidol and after switch to risperidone. Markianos M; Hatzimanolis J; Lykouras L Psychopharmacology (Berl); 1999 Apr; 143(3):270-2. PubMed ID: 10353429 [TBL] [Abstract][Full Text] [Related]
25. Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses. Levy MI; Davis BM; Mohs RC; Kendler KS; Mathé AA; Trigos G; Horvath TB; Davis KL Arch Gen Psychiatry; 1984 May; 41(5):520-4. PubMed ID: 6372737 [TBL] [Abstract][Full Text] [Related]
27. Growth hormone and prolactin response to apomorphine in schizophrenia and the major affective disorders. Relation to duration of illness and depressive symptoms. Meltzer HY; Kolakowska T; Fang VS; Fogg L; Robertson A; Lewine R; Strahilevitz M; Busch D Arch Gen Psychiatry; 1984 May; 41(5):512-9. PubMed ID: 6721674 [TBL] [Abstract][Full Text] [Related]
28. Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. Kapur S; Roy P; Daskalakis J; Remington G; Zipursky R Am J Psychiatry; 2001 Feb; 158(2):311-4. PubMed ID: 11156818 [TBL] [Abstract][Full Text] [Related]
29. Effect of neuroleptic withdrawal on plasma prolactin: a possible marker of receptor adaptation. Kirkpatrick B; Buchanan RW; Maeda K; Carpenter WT; Jauch D; Tamminga CA Biol Psychiatry; 1989 Jun; 26(2):131-8. PubMed ID: 2567610 [TBL] [Abstract][Full Text] [Related]
30. Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy. Ettigi P; Nair NP; Lal S; Cervantes P; Guyda H J Neurol Neurosurg Psychiatry; 1976 Sep; 39(9):870-6. PubMed ID: 993808 [TBL] [Abstract][Full Text] [Related]
31. Bromocriptine therapy in chronic schizophrenia: effects on symptomatology, sleep patterns, and prolactin response to stimulation. Brambilla F; Scarone S; Pugnetti L; Massironi R; Penati G; Nobile P Psychiatry Res; 1983 Mar; 8(3):159-69. PubMed ID: 6574535 [TBL] [Abstract][Full Text] [Related]
32. Platelet monoamine oxidase and the growth hormone response to apomorphine in schizophrenia. Malas KL; van Kammen DP; deFraites EA; Brown GM; Gold PW Biol Psychiatry; 1983 Feb; 18(2):255-9. PubMed ID: 6830934 [No Abstract] [Full Text] [Related]
33. Comparison of prolactin concentrations between haloperidol and risperidone treatments in the same female patients with schizophrenia. Yasui-Furukori N; Kondo T; Suzuki A; Mihara K; Kaneko S Psychopharmacology (Berl); 2002 Jun; 162(1):63-6. PubMed ID: 12107619 [TBL] [Abstract][Full Text] [Related]
34. Effect of dihydroergokryptine administration on serum prolactin and growth hormone levels in normal, hyperprolactinaemic and acromegalic subjects: evidence of potent and long-lasting pituitary dopamine receptor stimulation. Ferrari C; Rampini P; Paracchi A; Boghen M; Mailland F Eur J Clin Pharmacol; 1985; 27(6):707-11. PubMed ID: 3921384 [TBL] [Abstract][Full Text] [Related]
35. Neuroendocrine changes in acute schizophrenia as a function of clinical state and neuroleptic medication. Cotes PM; Crow TJ; Johnstone EC; Bartlett W; Bourne RC Psychol Med; 1978 Nov; 8(4):657-65. PubMed ID: 364517 [TBL] [Abstract][Full Text] [Related]
36. A controlled comparative study of chlorprothixene vs. haloperidol in chronic schizophrenia. Fux M; Belmaker RH Isr J Psychiatry Relat Sci; 1991; 28(1):37-40. PubMed ID: 1830565 [TBL] [Abstract][Full Text] [Related]
37. Haloperidol does not affect the level of serum-soluble interleukin-2 receptor in drug-free male schizophrenics. Kim CE; Kang DY; Ha KS; Jeong SH; Kim YS Biol Psychiatry; 1995 Dec; 38(12):843-5. PubMed ID: 8750045 [No Abstract] [Full Text] [Related]
38. Dopamine receptor responsivity in schizophrenic patients before and after switch from haloperidol to risperidone. Markianos M; Hatzimanolis J; Lykouras L Psychiatry Res; 1999 Dec; 89(2):115-22. PubMed ID: 10646830 [TBL] [Abstract][Full Text] [Related]
39. Prediction of outcome in first-episode schizophrenia. Lieberman JA J Clin Psychiatry; 1993 Mar; 54 Suppl():13-7. PubMed ID: 8097192 [TBL] [Abstract][Full Text] [Related]
40. Lithium prevents adaptation of brain dopamine systems to haloperidol in schizophrenic patients. Sternberg DE; Bowers MB; Heninger GR; Charney DS Psychiatry Res; 1983 Oct; 10(2):79-86. PubMed ID: 6581492 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]